Please login to the form below

Not currently logged in
Email:
Password:

Afferent Pharma

This page shows the latest Afferent Pharma news and features for those working in and with pharma, biotech and healthcare.

Merck says Afferent’s chronic cough drug clears mid-stage trial

Merck says Afferent’s chronic cough drug clears mid-stage trial

Merck says Afferent’ s chronic cough drug clears mid-stage trial. MK-7264 reduces coughs per hour by 37%. ... Merck &Co's purchase of Afferent Pharma last year was all about a candidate drug for chronic cough - so it will be celebrating now the drug

Latest news

  • Merck buys cough drug developer Afferent for $1.25bn Merck buys cough drug developer Afferent for $1.25bn

    Merck buys cough drug developer Afferent for $1.25bn. Gains access to pipeline with potential for development in ‘ neurogenic’ indications. ... Merck &Co has agreed a deal to buy California biopharma company Afferent Pharma, adding a drug candidate

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics